Network
Network
The EMIG Network includes approximately 1,500 individuals from Member companies and organisations, ranging from pharma companies to Associate Members offering vital services. Our membership also extends to patient charities, research organisations, and universities, all of which benefit from free membership.
Members can access collective expertise through our 'Network Questions' service. This allows any member to anonymously submit a question or request assistance via our web portal, with responses made freely available in the members' area.
Please can anyone advise if a new MAA is submitted in prior to Jan 2025 via a DCP, with Northern Ireland as a CMS
Has anyone successfully secured a positive NICE recommendation for a digital therapeutic using a real-world evidence (RWE) study design?
NHS Formulary Application Pack Development Support
Looking for a vendor with experience producing a Carbon Reduction Plan.
Can you help with a TOPRA MSc thesis?
Can anyone advise if the MHRA will accept a generic national MAA if the reference medicinal product is discontinued?
Request for recommendations for Irish oncology HTA consultant
Does anyone have experience of submitting a generic national MAA using a UK Reference Medicinal Product that has a licence (over 8 years old) but is discontinued?
We are looking for a medical affairs individual who works as a consultant for a part-time national role.
We are looking for a marketing agency to support us in developing a clear, structured, and user-friendly cost-effectiveness narrative for our NHS formulary pack applications.
We are looking to change our accountancy firm
Do members have experience supporting or managing Pharmacy Foundation Trainee posts that include an industry placement within cross-sector training?
What are the goals of category H introduction and is it aimed at branded generics only?
We are a small start up and need a simple, compliant way to capture consent from UK HCPs so we can send marketing and promotional emails.
Does anyone know of a legal firm that specialises in regulatory issues with the MHRA?
We are looking for a new PV, Regulatory agency to appoint in Q1 2026.
Does anyone know the legal position if the MHRA approves a variation and then 6 months later says it was approved in error and that we should submit another variation to revert the position?
Our expert clinician advisors in the NHS inform us there is no unmet needs in the data.
Can anyone recommend someone to give us support with renewing your Drug Tariff Part IX medical device listings
De-branding and primary care prescribing systems. How does it work and should there be concern over PI?
I am looking for guidance on how best to enforce the use of a licensed pharmaceutical as opposed to an unlicensed equivalent
Our technical team have been referred to the DHSC Medicines Supply Team but so far, they haven’t heard back.
Does anyone have experience of commercial discussions with NHS E where the Company has been asked to repay VAT on top of the commercial discount?
We have recently obtained our controlled drug licence from the Home Office and are currently using a hard copy controlled drug book to track the required information
We are developing a clinical decision-support tool that flags potential risk for rare or underdiagnosed conditions but does not provide diagnostic conclusions.